2025 Archives - MaaT Pharma

Press Releases

December 8, 2025: MaaT Pharma Presents Pivotal ARES Phase 3 Results for MaaT013 (Xervyteg®) in Acute GvHD at ASH 2025 Annual Congress and Announces 54% 1-Year Overall Survival

MaaT Pharma Presents Pivotal ARES Phase 3 Results for MaaT013 (Xervyteg®) in Acute GvHD at…

MaaT PharmaDecember 8, 2025

Media

November 28, 2025: French Tech : Maat Pharma, un anticancer issu du microbiote – BFM Business (French Only)

MaaT PharmaNovember 28, 2025

Event

SFGM-TC 2025

SFGM-TC 2025 - November 19-21, 2025

MaaT PharmaNovember 24, 2025

Event

Investir Day 2025

Investir Day 2025 - November 25, 2025

MaaT PharmaNovember 24, 2025

Event

ASH Annual Meeting

ASH 2025 - December 6-9, 2025

MaaT PharmaNovember 24, 2025

Press Releases

November 14, 2025: MaaT Pharma announces the successful completion of its Global Offering of €9.1 million

THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN IS RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION…

MaaT PharmaNovember 14, 2025

Press Releases

November 13, 2025: MaaT Pharma Launches a Capital Increase of Approximately €9 Million

THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN IS RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION…

MaaT PharmaNovember 13, 2025

Press Releases

November 5, 2025: MaaT Pharma Presents Updated Preclinical Data at SITC Annual Meeting Demonstrating Immune Activation and Anti-Tumor Activity of MaaT034

MaaT Pharma Presents Updated Preclinical Data at SITC Annual Meeting Demonstrating Immune Activation and Anti-Tumor…

MaaT PharmaNovember 5, 2025

Press Releases

November 4, 2025: MaaT Pharma Reports Financial Results for the Third Quarter 2025 and Provides Financing Update

MaaT Pharma Reports Financial Results for the Third Quarter 2025 and Provides Financing Update The…

MaaT PharmaNovember 4, 2025

Press Releases

November 3, 2025: MaaT Pharma Announces Positive Phase 3 Results Evaluating Xervyteg® (MaaT013) in Acute Graft-versus-Host Disease Selected for Oral Presentation at ASH Congress 2025

MaaT Pharma Announces Positive Phase 3 Results Evaluating Xervyteg® (MaaT013) in Acute Graft-versus-Host Disease Selected…

MaaT PharmaNovember 3, 2025

Rechercher un article

Filtrer par catégorie

Filtrer par date

Search an article

Filter by category

Filter by date

December 8, 2025: MaaT Pharma Presents Pivotal ARES Phase 3 Results for MaaT013 (Xervyteg®) in Acute GvHD at ASH 2025 Annual Congress and Announces 54% 1-Year Overall Survival

November 28, 2025: French Tech : Maat Pharma, un anticancer issu du microbiote – BFM Business (French Only)

SFGM-TC 2025

Investir Day 2025

ASH Annual Meeting

November 14, 2025: MaaT Pharma announces the successful completion of its Global Offering of €9.1 million

November 13, 2025: MaaT Pharma Launches a Capital Increase of Approximately €9 Million

November 5, 2025: MaaT Pharma Presents Updated Preclinical Data at SITC Annual Meeting Demonstrating Immune Activation and Anti-Tumor Activity of MaaT034

November 4, 2025: MaaT Pharma Reports Financial Results for the Third Quarter 2025 and Provides Financing Update

November 3, 2025: MaaT Pharma Announces Positive Phase 3 Results Evaluating Xervyteg® (MaaT013) in Acute Graft-versus-Host Disease Selected for Oral Presentation at ASH Congress 2025

COMPANY

Ressources

Contact